We present a case series of two patients who received cisplatin-based neoadjuvant chemotherapy and had pathologic node-positive urothelial carcinoma...Tumor next generation sequencing revealed high mutational burden in both patients and positive PD-L1 in one patient. Management and outcome: Patients were treated with adjuvant pembrolizumab and experienced long-term disease free intervals.